Holen Sie sich die Stockscreener-App
48.71
2.14%
1.02
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Assessing Vera Therapeutics (VERA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Does FDA Priority Review For Atacicept Reshape The Bull Case For Vera Therapeutics (VERA)? - Yahoo Finance
Will Vera Therapeutics Inc. stock split again soonJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - ulpravda.ru
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What risks investors should watch in Vera Therapeutics Inc. stockCEO Change & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Is Vera Therapeutics Inc. stock gaining market share2025 Growth vs Value & AI Powered Market Entry Ideas - ulpravda.ru
Upcoming EventsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Detailed Stock Data - FinancialContent
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Shift From Loss To Profit - 富途牛牛
Will Vera Therapeutics Inc. stock attract ESG investorsRisk Management & AI Powered Market Entry Ideas - ulpravda.ru
Is Vera Therapeutics Inc. stock a safe buy before earningsJuly 2025 Reactions & Community Driven Trade Alerts - ulpravda.ru
Los Angeles Daily NewsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Stock Quote - FinancialContent
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ - openPR.com
Why Vera Therapeutics Stock Zoomed Higher Today - The Globe and Mail
FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review - Investing.com Nigeria
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review By Investing.com - Investing.com South Africa
Vera Therapeutics shares up 3% after co receives U.S. FDA priority review for kidney disease drug - MarketScreener
Vera Therapeutics' Atacicept Receives FDA Priority Review for Treatment of IgAN with PDUFA Date Set for July 7, 2026 - Quiver Quantitative
New weekly shot for serious kidney disease gets priority FDA review - Stock Titan
FDA Expedites Approval of Vera’s Home-Based Kidney Medication - Bitget
Wells Fargo sees short squeeze ahead: here are three stocks to play it - CryptoRank
Vera Therapeutics Earnings Notes - Trefis
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
450,700 Shares in Vera Therapeutics, Inc. $VERA Acquired by Capricorn Fund Managers Ltd - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - ts2.tech
Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year HighShould You Buy? - MarketBeat
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects - Sahm
Vera Therapeutics Appoints James R. Meyers to Board - MSN
Vera’s New Capital Raise and Legal Transition Might Change The Case For Investing In Vera Therapeutics (VERA) - Sahm
How risky is Vera Therapeutics Inc. stock now2025 Market Overview & Smart Swing Trading Alerts - Улправда
Weekly Earnings: How Vera Therapeutics Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Momentum Based Trading Ideas - ulpravda.ru
Recap Report: Will Vera Therapeutics Inc. stock attract ESG investorsLong Setup & Long-Term Safe Investment Plans - moha.gov.vn
Vera Therapeutics, Inc. $VERA Shares Acquired by Squarepoint Ops LLC - MarketBeat
Goldman Sachs Maintains Vera Therapeutics (VERA) Buy Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 51.23 USD By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Vera Therapeutics Investors Drop Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics stock hits 52-week high at 51.23 USD - Investing.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Given New $96.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Is Vera Therapeutics Inc. stock oversold or undervalued2025 Market Trends & Fast Gain Swing Alerts - Улправда
Goldman Sachs raises Vera Therapeutics stock price target to $95 on IgAN pricing - Investing.com Canada
Vera Therapeutics stock price target raised to $66 by BofA Securities - Investing.com Canada
Will Vera Therapeutics Inc. stock maintain growth storyIndex Update & Weekly Breakout Watchlists - DonanımHaber
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):